Tag Archives: bladder cancer

March, 2017

  • 31 March

    Incyte, Merck Provide Details on Collaboration of Epacadostat and Keytruda

    WILMINGTON, Del. & KENILWORTH, N.J.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with KEYTRUDA®(pembrolizumab), Merck’s anti-PD-1 therapy, in patients across five …

February, 2017

  • 27 February

    Bristol-Myers Squibb and Exelixis Partner for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma

    SOUTH SAN FRANCISCO, Calif. & NEW YORK–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical development collaboration to evaluate CABOMETYX™ (cabozantinib), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, with Opdivo (nivolumab), Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, either alone or …

  • 3 February

    FDA Accepts Two sBLA’s for Merck’s Keytruda

    KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial cancer, a …

  • 3 February

    FDA Approves Bristol-Myers Squibb’s Opdivo for Treatment of Bladder Cancer

    PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo injection, for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 …

January, 2017

December, 2016

October, 2016

  • 21 October

    Merck’s Keytruda Succeeds in Late-Stage Bladder Cancer Trial

    KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA®(pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS). In this trial, KEYTRUDA …

June, 2016

January, 2016

  • 8 January

    Roche Announces Encouraging Results from its Bladder Cancer Study

    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated results from the pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy atezolizumab (MPDL3280A) in people with locally advanced or metastatic urothelial carcinoma (mUC). Median overall survival (mOS) in this heavily pre-treated population was 11.4 months [95% CI: 9.0, …